AusperBio Closes $120M Series C For Hepatitis B ASO Therapy
SHERIDAN, WYOMING -- August 27, 2026 -- AusperBio Therapeutics closed a $120 million Series C financing round on Aug. 27, 2026, bringing its total capital raised since 2024 to $360 million. The San Francisco-based biopharmaceutical company will direct proceeds toward Phase 3 registrational work and commercialization readiness for AHB-137, its lead antisense oligonucleotide therapy for chronic hepatitis B. RA Capital Management, L.P. joined the round as a new investor alongside an unnamed lead strategic investor.
Existing backers HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments also participated. AusperBio described the round as reflecting sustained investor confidence in its oligonucleotide platforms.